Dr. Sue

Blog
I am a medical doctor, Specialist in Endocrinology & Metabolism, and a Diplomate of the American Board of Obesity Medicine. After completing my training as an Endocrinologist in 2005 at the University of Calgary, I have worked in Calgary, at the Royal University Hospital in Saskatchewan, and at the University of Copenhagen in Denmark. I have a busy clinical practice at C-ENDO Diabetes and Endocrinology Clinic in Calgary, caring for patients with diabetes, obesity, thyroid, and other hormone issues. I am also involved in clinical research in diabetes and obesity. I am a member of the Expert Committee for the 2018 Diabetes Canada Guidelines, and lead author of the Pharmacotherapy Chapter of the 2020 Canadian Obesity Guidelines. I am passionate, enthusiastic, and driven to help conquer the stigma against obesity; educate health care professionals and the public about obesity, diabetes, and healthy living; and to help us become a healthier society! Source

Actions

Share this page

Media Outlet details

Scope Local
Language English
Country Canada
Similarweb UVMSimilarweb UVM Request pricing
Comscore UVMComscore UVM Request pricing

Recent Articles

Search

Do GLP1 based weight management medications benefit liver health?

|
By Sue D Pedersen
| Dr. Sue
Prefer to listen? Check out my podcast here! Metabolic dysfunction-associated steatotic liver disease (MASLD) and steatohepatitis (MASH) (formerly called fatty liver disease or NASH) is extremely common, affecting about 1 in 4 adults globally. In people with obesity, about 75% have MASLD, and about 1 in 3 have MASH. In people with elevated weight, MASLD/MASH can improve with weight loss. Today’s question is: can GLP1-based weight loss medications benefit liver health in people with MASH?
Open in Who Shared Issue with article?

What happens if you stop weight management medication, and what do our new Obesity Canada Guidelines advise?

|
By Sue D Pedersen
| Dr. Sue
Prefer to listen? Check out my podcast here! In my clinical practice, the topic of ‘what will happen if I stop my weight management medication?’ often comes up. There are many reasons why this question can arise. For one, these medications are expensive. Many people are paying out-of-pocket, and the cost continues as long as the person is taking medication.
Open in Who Shared Issue with article?

OBESITY CANADA 2025 PHARMACOTHERAPY GUIDELINES: WHAT COULDN’T WE ANSWER?

|
By Sue D Pedersen
| Dr. Sue
Prefer to listen? Check out my podcast here! A week ago today, we released our Obesity Canada 2025 Pharmacotherapy Clinical Practice Guidelines update (disclosure: I am the lead author). While it’s wonderful that we now have data to generate recommendations on seven obesity-related health conditions, and more medication choices than we had just a few years ago, there are still so many gaps that need to be filled. Where does lack of data leave our Guidelines wanting for more?
Open in Who Shared Issue with article?

Scale up your practice! Check out Obesity Canada podcast on our new 2025 Pharmacotherapy Guidelines

|
By Sue D Pedersen
| Dr. Sue
In follow up to this week’s big news that our 2025 Obesity Canada Pharmacotherapy Clinical Practice Guidelines are now published (disclosure: I am the lead author), here is a fun and informative podcast we recorded, hosted by Dr Roshan Abraham and Michelle McMillan. Enjoy! Subscribe to my blog! (upper right) Check me out on Insta: drsuepedersen Share this blog post using your favorite social media link below! www.drsue.ca © 2025
Open in Who Shared Issue with article?

OBESITY CANADA PHARMACOTHERAPY clinical practice GUIDELINES 2025 - PUBLISHED!

|
By Sue D Pedersen
| Dr. Sue
Prefer to listen? Check out my podcast here! I am so deeply honored – and excited! – to share with you that we have now published the long-awaited 2025 Obesity Canada Pharmacotherapy Clinical Practice Guideline! It has been an absolute honor (and labor of love!) to build these guidelines together with my co-authors Drs Priya Manjoo, Satya Dash, Akshay Jain, Megha Poddar, and Ms. Nicole Pearce. Our full guideline is published on the Obesity Canada website.
Open in Who Shared Issue with article?

Can weight loss medications improve erectile dysfunction (ED)?

|
By Sue D Pedersen
| Dr. Sue
Prefer to listen? Check out my podcast here! Erectile dysfunction (ED) is common in men with elevated weight.
Open in Who Shared Issue with article?

How does Mounjaro stack up for cardiovascular protection? The SURPASS CVOT results

|
By Sue D Pedersen
| Dr. Sue
Prefer to listen? Check out my podcast here! In choosing the best GLP1-based medication for our patients with type 2 diabetes at high risk of cardiovascular disease, guidelines recommend choosing one that has proven reduction in risk of CV events in cardiovascular outcome trials (CVOTs). The three marketed GLP1 receptor agonists that have previously met this bar are dulaglutide (Trulicity), liraglutide (Victoza), and semaglutide (Ozempic as an injection, and Rybelsus as a pill).
Open in Who Shared Issue with article?

Can creatine supplements preserve muscle during weight loss?

|
By Sue D Pedersen
| Dr. Sue
Prefer to listen? Check out my podcast here! When people with elevated weight lose weight with any currently available treatment modality (lifestyle changes, weight loss medications, or bariatric surgery), about 1/3 of the weight is lost as muscle, and 2/3 of the weight is lost as fat.
Open in Who Shared Issue with article?

Sleep Is A Nutrient!

|
By Sue D Pedersen
| Dr. Sue
Prefer to listen? Check out my podcast here! We often talk about sleep as a luxury in busy lives, a casualty of work, kids, stress, screens, and schedules. In fact, it often seems strangely revered or worthy of bragging rights to be one of ‘those people’ who can burn the candle at both ends and thus be seemingly ‘more productive’ by getting less sleep. But what if we redefined sleep entirely? What if we thought of sleep like an essential vitamin – non-negotiable, restorative, and vital?
Open in Who Shared Issue with article?

Could GLP1 weight loss/diabetes medications benefit skin conditions like psoriasis or hidradenitis suppurativa?

|
By Sue D Pedersen
| Dr. Sue
Prefer to listen? Check out my podcast here! As we gain 20+ years of experience with GLP1-based treatment, I continue to be fascinated by the diversity of potential benefits that we are finding in clinical trials and in clinical practice. A fascinating article was recently published reviewing the potential benefits of GLP1-based medication to skin conditions. Psoriasis is an autoimmune condition that has been hypothesized to benefit from GLP1 medication.
Open in Who Shared Issue with article?